XML 50 R40.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitments and Contingencies (Details Narrative) |  |  |  |  | 3 Months Ended | 6 Months Ended
--- | --- | --- | --- | --- | --- | ---
Feb. 07, 2022 USD ($) | Nov. 19, 2021 ft² | Mar. 26, 2021 USD ($) | Oct. 05, 2020 | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($) | Jun. 30, 2022 USD ($) | Jun. 30, 2021 USD ($)
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Litigation settlement expense | $ 425,000 |  |  |  |  |  |  |
Project fee |  |  |  |  |  |  | $ 2,100,000 |
Recorded expenses |  |  |  |  | $ 192,000,000,000 |  | 383,000,000,000 |
Other commitments, description |  |  |  | On October 5, 2020, GT Biopharma entered into a Master Services Agreement with a third-party product manufacturer to perform biologic development and manufacturing services on behalf of the Company. Associated with this, the Company has subsequently signed five Statements of Work for the research and development of products for use in clinical trials. At June 30, 2022, the Company’s commitments in relation to these Statements of Work and any related Change Orders totaled approximately $13.0 million, of which $9.8 million was incurred at that date and an additional $3.2 million is in process during fiscal year 2022. |  |  |  |
Research and development expense |  |  |  |  | 1,139,000 | $ 639,000 | 3,226,000 | $ 2,279,000
Rent expense |  |  |  |  | 29,000 |  | 58,000 |
Aimmune Therapeutics Inc [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Area of land | ft² |  | 4,500 |  |  |  |  |  |
Commencement date |  | commencement date of January 1, 2022 and maturing on June 30, 2024 |  |  |  |  |  |
Master Services Agreement [Member] | Cytovance Biologics, Inc. [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Commitment amount for services, total |  |  |  |  |  |  | 13,000,000.0 |
Commitment cost incurred |  |  |  |  |  |  | 9,800,000 |
Compensation cost expected to be incurred in future |  |  |  |  |  |  | 3,200,000 |
Research And Development Agreements [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 92,000,000 |  | 1,180,000,000 |
2016 Patent License Agreement [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Proceeds from upfront amount |  |  |  |  | 200,000 |  | 200,000 |
Maintanance fee |  |  |  |  |  |  | $ 100,000 |
Royalty fee percentage |  |  |  |  |  |  | 0.04 |
Performance milestone payments |  |  |  |  |  |  | $ 3,100,000 |
Sales milestone payments |  |  |  |  |  |  | 1,000,000.0 |
Gross sales |  |  |  |  |  |  | 250,000,000 |
Sales revenue |  |  |  |  |  |  | 5,000,000.0 |
Cummulative gross sales |  |  |  |  |  |  | 500,000,000 |
2016 Patent License Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Annual royalty payments |  |  |  |  |  |  | 250,000 |
2016 Patent License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Annual royalty payments |  |  |  |  |  |  | 5,000,000.0 |
2016 Exclusive Patent License Agreement [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 0 |  | 0 |
2021 Patent License Agreement [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 0 |  | 0 |
Annual royalty payments |  |  |  |  |  |  | 250,000 |
Performance milestone payments |  |  |  |  |  |  | 3,100,000 |
Sales milestone payments |  |  |  |  |  |  | 1,000,000.0 |
Gross sales |  |  |  |  |  |  | 250,000,000 |
Sales revenue |  |  |  |  |  |  | 5,000,000.0 |
Cummulative gross sales |  |  |  |  |  |  | 500,000,000 |
Upfront license fee |  |  | $ 20,000 |  |  |  |  |
License maintenance fee, receivable |  |  |  |  | $ 5,000 |  | 5,000 |
Maintanance fee |  |  |  |  |  |  | $ 2,000,000.0 |
2021 Patent License Agreement [Member] | Minimum [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Net sales percentage |  |  |  |  |  |  | 0.025 |
2021 Patent License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |
Net sales percentage |  |  |  |  |  |  | 0.05 |

X
- Definition Annual maintanance fee. + References No definition available. + Details
Name: | GTBP_AnnualMaintananceFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Annual royalty payments. + References No definition available. + Details
Name: | GTBP_AnnualRoyaltyPayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cummulative gross sales. + References No definition available. + Details
Name: | GTBP_CummulativeGrossSales
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gross sales. + References No definition available. + Details
Name: | GTBP_GrossSales
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License maintenance fee, receivable. + References No definition available. + Details
Name: | GTBP_LicenseMaintenanceFeeReceivable
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maintanance fee. + References No definition available. + Details
Name: | GTBP_MaintananceFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Net sales percentage. + References No definition available. + Details
Name: | GTBP_NetSalesPercentage
Namespace Prefix: | GTBP_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Performance milestone payments. + References No definition available. + Details
Name: | GTBP_PerformanceMilestonePayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Received upfront payment. + References No definition available. + Details
Name: | GTBP_ProceedsFromUpfrontAmount
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Project fee. + References No definition available. + Details
Name: | GTBP_ProjectFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Recorded expenses. + References No definition available. + Details
Name: | GTBP_RecordedExpenses
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Compensation cost expected to be incurred in future. + References No definition available. + Details
Name: | GTBP_ResearchAndDevelopmentArrangementContractToPerformExpectedCostsIncurred
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research and development arrangement contract to perform for others costs incurred. + References No definition available. + Details
Name: | GTBP_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurred
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty fee percentage. + References No definition available. + Details
Name: | GTBP_RoyaltyFeePercentage
Namespace Prefix: | GTBP_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales milestone payments. + References No definition available. + Details
Name: | GTBP_SalesMilestonePayments
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sales revenue. + References No definition available. + Details
Name: | GTBP_SalesRevenue
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront license fee. + References No definition available. + Details
Name: | GTBP_UpfrontLicenseFee
Namespace Prefix: | GTBP_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Area of land held. + References No definition available. + Details
Name: | us-gaap_AreaOfLand
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:areaItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of terms and conditions of option to extend operating sublease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingSubleaseOptionToExtend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. + References No definition available. + Details
Name: | us-gaap_LitigationSettlementExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the nature and terms of commitment. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsDescription
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash payments to lessor's for use of assets under operating leases. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=GTBP_AimmuneTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_MasterServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=GTBP_CytovanceBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_ResearchAndDevelopmentAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenPatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandSixteenExclusivePatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=GTBP_TwoThousandAndTwentyOnePatentLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |